SMMT is one of three companies open in full. Every company in our coverage universe has a thesis like this one.
Sign up freeSummit, BioNTech, more headline WCLC with next-gen lung cancer drugs - BioSpace
BioSpace · Sep 14, 3:30 PM
Akeso, Summit’s ivonescimab tops Keytruda in lung cancer survival, with strong data in PD-L1-high patients - Fierce Pharma
Fierce Pharma · Sep 13, 1:45 AM
Updated today
Summit Therapeutics is a clinical-stage biopharmaceutical company developing ivonescimab, a targeted cancer drug for non-small-cell lung cancer in patients whose tumors have an EGFR mutation and who have already received prior chemotherapy, which is not yet approved.
HARMONi-2 reported HR 0.73 versus pembrolizumab at 36-month follow-up, the first head-to-head OS win over Keytruda in first-line NSCLC. The thesis resolves on whether FDA accepts the largely China-conducted dataset as sufficient for the November 2026 BLA decision on the EGFRm post-TKI indication. At $147M quarterly burn against $691M cash, the company has roughly four to five quarters of runway, creating a financing dependency that a going-concern disclosure has now formalized.
Current Thesis Drivers
What could change the thesis?
Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.
HARMONi Phase III BLA catalyst advanced with June 2026 OS data (HR 0.76, 23.2-month western follow-up); HARMONi-2 achieved OS HR 0.73 ivonescimab vs pembrolizumab; HARMONi-GU1 Phase II/III initiated in urothelial carcinoma.
The full HARMONi-2 OS dataset showing HR 0.73 versus pembrolizumab was presented at WCLC 2026 in September, adding a head-to-head superiority result that was not part of the evidentiary record when the prior status was set, yet the November 2026 PDUFA for the EGFRm BLA remains the unresolved gate and FDA has not signaled acceptance of the updated submission.
Source ↗Akeso's Phase III HARMONi-GI1 achieved statistically significant OS superiority with ivonescimab + chemotherapy vs. durvalumab + chemotherapy in first-line advanced biliary tract cancer.
Summit disclosed a going-concern risk in July 2026 filings, flagging uncertainty about cash adequacy without additional capital, even as the BLA review proceeds toward a November 2026 PDUFA date.
Source ↗HARMONi Phase III updated OS analysis demonstrates ivonescimab + chemotherapy achieves HR 0.76 across western and ITT populations with consistent safety, supporting pending FDA BLA decision.
Summit launched and withdrew a $500M equity offering within one day in June 2026, signaling it cannot readily access capital at acceptable terms while burning $122M per quarter with a PDUFA date still months away.
Source ↗Summit Therapeutics withdrew a $500M stock offering after two days due to unfavorable market conditions.
Summit's withdrawal of a $500M equity offering within one day of announcement signals that the company could not price the raise at acceptable terms, creating financing uncertainty at a burn rate of $122M per quarter with approximately five quarters of runway remaining from the April 2026 cash balance.
Source ↗Ivonescimab + mFOLFOX6 achieved 70.8% ORR in Phase II mCRC, supporting advancement to Phase III HARMONi-GI3 trial with manageable safety profile.
FDA accepted the BLA with a PDUFA date of November 14, 2026, and the longer-term OS analysis achieved nominal statistical significance (HR 0.78, p=0.0332), keeping the core regulatory thesis on track without new negative signals.
Source ↗ivonescimab · Non-small cell lung cancer · PD-L1 positive · advanced
The HARMONi-2 Phase III trial, presented at a medical congress with a 36-month median follow-up, demonstrated that ivonescimab monotherapy produced a statistically significant improvement in overall survival versus pembrolizumab monotherapy in patients with first-line advanced PD-L1-positive non-small cell lung cancer (HR 0.73, 95% CI: 0.57–0.95; p=0.009). Median OS was 30.8 months in the ivonescimab arm compared with 22.6 months in the pembrolizumab arm. Benefit was consistent across PD-L1 expression subgroups and histologic subtypes, and no new safety signals were identified. The readout confirmed the OS endpoint in this head-to-head monotherapy comparison and provides the primary efficacy dataset supporting ivonescimab's regulatory program in this indication.